среда, 22 июня 2016 г.

Drug Stocks Surge as U.S. Says Cost Panel to Wait Until 2017

Drug Stocks Surge as U.S. Says Cost Panel to Wait Until 2017


Drug and biotechnology stocks surged Wednesday after the U.S. government said a cost-cutting mechanism created under Obamacare, known as the Independent Payment Advisory Board, or IPAB, will likely be triggered in 2017, not this year as some investors had feared. The 2017 projection is in line with estimates from last year by Medicare's Board of Trustees, which on Wednesday released its annual report on the U.S. health-care program's long-term finances.



from Biotech News